Tarsus Pharmaceuticals, Inc.
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
LINK WILLIAM J PHD sold 12,500 shares of Tarsus Pharmaceuticals, Inc. (TARS) at an average of $78.38 ($78.33–$80.01, $0.98M total) across 3 trades on 2026-09-15 under a Rule 10b5-1 trading plan.
Barclays reinstated Tarsus Pharmaceuticals (TARS) with an Overweight rating and a $110.00 price target. The company's stock is currently trading at $78.23, with a GF Value™ of $160.86, indicating a 51.4% undervaluation. TARS has a GF Score™ of 46/100, reflecting mixed financial health and performance. The company focuses on biotechnology, particularly eye care, with its lead product being XDEMVY.
Tarsus Pharmaceuticals, Inc. (TARS) filed an SEC Form 8-K — Completion of Acquisition or Disposition of Assets. Tarsus Pharmaceuticals Completes Acquisition of Alkeus Pharmaceuticals, Expanding Leadership in Eye Care September 4, 2026 Adds gildeuretinol (ALK-001), a differentiated Phase 3 oral investigational medicine designed to target the underlying biology of Stargardt’s disease, a pote
Over the past 7 days, AlphAI's AI scored 1 news story mentioning TARS (Tarsus Pharmaceuticals, Inc.). Coverage has skewed bullish: 1 bullish, 0 neutral, and 0 bearish.
Recent TARS coverage spans insider activity, mergers & acquisitions and financial news.
In the last 30 days, TARS insiders filed 14 SEC Form 4 transactions — no purchases and 14 sales ($5.2M). The most active reporter was Lin Elizabeth Yeu, Chief Medical Officer, with 7 filings. 100% of those filings were made under pre-arranged Rule 10b5-1 plans.
Insider sale may signal lack of confidence, could pressure stock short-term.
Analyst upgrade signals expected outperformance and may drive short‑term buying pressure.
The deal expands Tarsus' eye‑care portfolio and could boost its valuation if ALK-001 succeeds.
Insider sale may signal confidence level but size is modest relative to market cap.
Insider sale may signal lack of confidence, potential short-term pressure on the stock.
AlphAI scores every news story that mentions TARS with an AI model for sentiment and relevance, and aggregates insider trades from Tarsus Pharmaceuticals, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
LINK WILLIAM J PHD sold 12,500 shares of Tarsus Pharmaceuticals, Inc. (TARS) at an average of $78.38 ($78.33–$80.01, $0.98M total) across 3 trades on 2026-09-15 under a Rule 10b5-1 trading plan.
1 min readBarclays reinstated Tarsus Pharmaceuticals (TARS) with an Overweight rating and a $110.00 price target. The company's stock is currently trading at $78.23, with a GF Value™ of $160.86, indicating a 51.4% undervaluation. TARS has a GF Score™ of 46/100, reflecting mixed financial health and performance. The company focuses on biotechnology, particularly eye care, with its lead product being XDEMVY.
2 min readTarsus Pharmaceuticals, Inc. (TARS) filed an SEC Form 8-K — Completion of Acquisition or Disposition of Assets. Tarsus Pharmaceuticals Completes Acquisition of Alkeus Pharmaceuticals, Expanding Leadership in Eye Care September 4, 2026 Adds gildeuretinol (ALK-001), a differentiated Phase 3 oral investigational medicine designed to target the underlying biology of Stargardt’s disease, a pote
2 min readAzamian Bobak R. (President/CEO and Board Chair) sold 10,000 indirectly-held shares of Tarsus Pharmaceuticals, Inc. (TARS) at an average of $90.56 ($90.27–$91.27, $0.91M total) across 2 trades on 2026-09-04 under a Rule 10b5-1 trading plan.
1 min readLin Elizabeth Yeu (Chief Medical Officer) sold 10,773 shares of Tarsus Pharmaceuticals, Inc. (TARS) at an average of $87.50 ($85.00–$90.00, $0.94M total) across 2 trades on 2026-09-04 under a Rule 10b5-1 trading plan.
1 min readJefferies raised its price target on Tarsus Pharmaceuticals (NASDAQ:TARS) to $105, citing strong guidance and recent prescription data. The stock has surged 23% in the past week. Tarsus reported Q2 2026 sales of $173.9M, beating expectations, and raised full-year sales guidance for XDEMVY. The company has a market cap of approximately $4B and is considered undervalued by InvestingPro analysis.
2 min readTarsus Pharmaceuticals (TARS) completed its acquisition of Alkeus Pharmaceuticals, gaining worldwide rights to ALK-001, a Phase 3 investigational therapy for Stargardt disease. ALK-001 has received multiple FDA designations and is expected to report topline data in 2029. The acquisition expands Tarsus' pipeline and supports its eye care strategy. TARS shares closed at $83.21 on Thursday, up 0.54%.
2 min readTarsus Pharmaceuticals (TARS) completed its acquisition of Alkeus Pharmaceuticals, gaining worldwide rights to ALK-001, a late-stage oral therapy for Stargardt disease. ALK-001 has received multiple FDA designations and is in a Phase 3 trial with topline data expected in 2029. Tarsus believes ALK-001 could be a blockbuster treatment for this inherited retinal disease with no FDA-approved therapies.
2 min readAzamian Bobak R. (President/CEO and Board Chair) sold 10,000 indirectly-held shares of Tarsus Pharmaceuticals, Inc. (TARS) at $80.06 ($0.80M total) on 2026-09-02 under a Rule 10b5-1 trading plan.
1 min readLin Elizabeth Yeu (Chief Medical Officer) sold 9,988 shares of Tarsus Pharmaceuticals, Inc. (TARS) at an average of $77.17 ($73.86–$80.00, $0.77M total) across 2 trades over 2026-09-01 to 2026-09-02 under a Rule 10b5-1 trading plan.
1 min read